The Breast Oncology Program (Program) is comprised of 39 Program Members from 13 different UCSF departments. The Program supports and stimulates basic, clinical, and population research in breast cancer and facilitates the translation of these findings into improved cancer management and control. The Program's themes are as follows: (1) epidemiology and etiology;(2) cancer prevention, risk models, and early detection;(3) genetics and biology of cancer progression;(4) new therapeutic targets and approaches;and (5) outreach, clinical care delivery, and outcomes. Research in the Program is supported by the Bay Area Breast Cancer SPORE, eight large multi-disciplinary, multi-institutional projects that support work in one or more themes, a multi-campus University of California Office of the President sponsored ATHENA Breast Health Network integrating clinical care and research by numerous individual investigator-initiated grants. Since the last competitive renewal much effort has been dedicated towards investigator initiated therapeutic trials, innovative companion diagnostic clinical trials, testing new radiation oncology treatment delivery systems including correlative science, as well as establishing a CLIA-compliant testing laboratory and an integrative bioinformatics and IT infrastructure. The Program has become more cohesive, has a high level of interaction that has led to new grant funding with joint program and project leaders and co-investigators across disciplines. Interactions between Program members are encouraged in several discussion forums, including a weekly multidisciplinary seminar, an annual retreat, a weekly tumor board, a bi-weekly breast site study review meeting, a monthly community forum, and a patient-physician management discussion series. The Program has $22,189,900 total peer-reviewed support for the last budget year. The Program has 17% intra-programmatic and 17% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693931
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$71,889
Indirect Cost
$26,224
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications